Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.77
+0.06820.28%
Post-market: 24.820.0518+0.21%19:30 EDT
Volume:23.89K
Turnover:594.14K
Market Cap:55.60M
PE:- -
High:25.07
Open:25.01
Low:24.73
Close:24.70
52wk High:27.02
52wk Low:15.63
Shares:2.24M
Float Shares:2.24M
Volume Ratio:0.61
T/O Rate:1.06%
Dividend:1.70
Dividend Rate:6.88%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Strata Mental Health Solutions awarded training grant by Compass Pathways

TIPRANKS
·
Sep 12

Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

MT Newswires Live
·
Sep 12

Dupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi

TIPRANKS
·
Sep 12

NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System

MT Newswires Live
·
Sep 11

Relmada CFO Maged Shenouda Acquires $843,140 of Common Shares

Reuters
·
Sep 11

GH Research to Hold One-on-One Investor Meetings at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 11

Evion Moves to Cancel Unpaid Placement Shares and Options

TIPRANKS
·
Sep 11

Vanadium Resources Plans Major Share and Option Placement on ASX

TIPRANKS
·
Sep 11

Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy

TIPRANKS
·
Sep 10

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

TIPRANKS
·
Sep 10

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS
·
Sep 10

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training

THOMSON REUTERS
·
Sep 10

Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14

Reuters
·
Sep 10

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug

Reuters
·
Sep 09

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year

THOMSON REUTERS
·
Sep 09

Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4

THOMSON REUTERS
·
Sep 09

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS
·
Sep 09

Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings

THOMSON REUTERS
·
Sep 09